A 56-year-old woman with a 20-year history of Raynaud phenomenon and sclerotic changes at the fingertips and face presented after progressive respiratory and systemic decline. She had chronic dry cough for one year and developed exertional shortness of breath over the month before presentation. Routine blood testing identified moderate anemia. Serum biochemistry revealed impaired renal function. Urinalysis showed proteinuria and occult blood. Immunological testing returned positive for anti-topoisomerase I (anti-SCL-70). Chest CT demonstrated interstitial fibrosis in both lower lungs. Based on these findings, the treating team diagnosed systemic sclerosis with chronic renal injury and initiated low-dose prednisone and nifedipine. The article is a single case report; it did not provide a comprehensive steroid taper schedule beyond describing the initial low-dose prednisone.
The patient's renal function worsened rapidly during follow-up. Repeat immunologic testing revealed positivity for anti-myeloperoxidase (MPO) antibody. Renal pathology from biopsy showed features consistent with crescentic glomerulonephritis. The study team concluded that the renal injury was driven by an anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) process superimposed on the background of systemic sclerosis. Treatment was escalated: methylprednisolone 500 mg was administered initially; when the clinical picture progressed the regimen was increased to methylprednisolone 1 g daily for three days. The authors reported adjunctive interventions including therapeutic plasma exchange and cyclophosphamide. The report lists these therapies exactly as administered; it did not detail cumulative cyclophosphamide doses or long-term immunosuppressive maintenance plans.
One day after the initial methylprednisolone pulse the patient developed hemoptysis. The care team interpreted this as alveolar hemorrhage and escalated high-dose steroids and supportive measures, including plasma exchange and cyclophosphamide. Three days after that escalation the patient vomited coffee-colored material and passed melena, findings the authors attributed to gastrointestinal hemorrhage; steroid dosing was reduced to 80 mg of methylprednisolone and acid suppression was added while plasma exchange and cyclophosphamide continued. The case therefore documents sequential major bleeding events affecting the lungs and gastrointestinal tract in temporal proximity to aggressive immunosuppression. After initial stabilization and discharge, the patient returned with pulmonary infection; while receiving anti-infective therapy she experienced recurrent gastrointestinal hemorrhage accompanied by cerebral hemorrhage and subsequently died. The report does not provide invasive hemostatic procedure details or autopsy findings to clarify the source of the cerebral bleed.
The patient’s course was complicated and episodic. Initial escalation of immunotherapy produced a period of clinical control sufficient for discharge. However, one month later she developed pulmonary infection identified by new respiratory symptoms and CT changes; the authors reported that during treatment of that infection she again developed gastrointestinal bleeding and then cerebral hemorrhage, events that led to death. The narrative links severe vasculitic activity—renal crescents and MPO positivity—with a propensity toward life-threatening hemorrhagic complications (alveolar and cerebral). The case report documents the sequence of treatments and complications but does not present detailed microbiology from the pulmonary infection or imaging chronology for the cerebral hemorrhage beyond the clinical assertion that these events occurred during readmission.
Investigators reported that coexistence of systemic sclerosis and AAV is rare and dangerous, with kidney involvement commonly manifesting as crescentic glomerulonephritis. The authors observed that development of alveolar hemorrhage or cerebral hemorrhage in this setting was associated with high mortality in their patient. Clinicians should therefore maintain vigilance for evolving vasculitis in SSc patients who develop rapid renal decline or new hemoptysis. This report has inherent limitations as a single-case description: it does not provide population-level incidence, comparative outcomes, or granular dosing and supportive measures beyond the methylprednisolone pulses, plasma exchange and cyclophosphamide noted. The source did not report full timing or cumulative dosing for all agents, detailed microbiological data for the pulmonary infection, nor autopsy confirmation of the cerebral hemorrhage etiology. These unanswered details limit causal attribution between therapies, infection, and the fatal hemorrhages and represent clear areas for further case series or systematic study.